Drug Profile
Parkinson's disease gene therapy - Oxford BioMedica
Alternative Names: AXO Lenti PD; OXB-101; OXB-102; ProSavin; Tricistronic lentiviral vector encoding for TH, AADC and CH1 - Oxford BioMedicaLatest Information Update: 19 May 2023
Price :
$50
*
At a glance
- Originator Oxford BioMedica
- Class Antiparkinsonians; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Parkinson's disease
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 19 May 2023 AXO-Lenti-PD is available for licensing as of 19 May 2023 (https://www.oxb.com/client-portfolio-and-gene-therapeutics-pipeline)
- 11 Aug 2022 Discontinued - Phase-II for Parkinson's disease in France (Intrastriatal)
- 11 Aug 2022 Discontinued - Phase-II for Parkinson's disease in United Kingdom (Intrastriatal)